These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16483340)

  • 1. Contemporary treatment of coronary bifurcations with drug-eluting stent: part II.
    Colombo A
    J Interv Cardiol; 2006 Feb; 19(1):51-3. PubMed ID: 16483340
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of sirolimus-eluting stent implantation for the treatment of coronary artery disease in octogenarians.
    Vijayakumar M; Lemos PA; Hoye A; Ong AT; Aoki J; Granillo GR; McFadden EP; Sianos G; Hofma SH; Smits PC; van der Giessen WJ; de Feyter P; van Domburg RT; Cummins PA; Serruys PW
    Am J Cardiol; 2004 Oct; 94(7):909-13. PubMed ID: 15464675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet glycoprotein IIb/IIIa receptor inhibitors: is their future as bright as their past?
    Leesar MA
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):907-8. PubMed ID: 18498141
    [No Abstract]   [Full Text] [Related]  

  • 4. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial comment: which is the preferred drug-eluting stent?
    Brodie BR
    J Interv Cardiol; 2006 Feb; 19(1):39-42. PubMed ID: 16483338
    [No Abstract]   [Full Text] [Related]  

  • 6. The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions.
    Ray GM; Nawarskas JJ; Frishman WH
    Cardiol Rev; 2006; 14(3):143-50. PubMed ID: 16628023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) -- a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents.
    Kumar S; Suresh V; Prendergast BD; Brooks NH; Wicks P; Levy RD; Ray SG; Bennett DH; Lee HS
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):663-8. PubMed ID: 17034063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent.
    Beijk MA; Piek JJ
    Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Status of drug-eluting coronary stents.
    Chodosh A; Korr KS; Burtt D
    Med Health R I; 2008 Oct; 91(10):309-12, 314. PubMed ID: 19044106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Percutaneous coronary intervention].
    Csapó K
    Orv Hetil; 2005 Mar; 146(13):587-93. PubMed ID: 15856622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What will be the impact of drug-eluting stents on hybrid coronary revascularization?
    Karamanoukian HL
    Heart Surg Forum; 2002; 5(4):E24-7. PubMed ID: 12538126
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of BMS in the drug eluting stent era: is still there any place for them?
    Fineschi M; Gori T
    Catheter Cardiovasc Interv; 2006 Sep; 68(3):456; author reply 457. PubMed ID: 16892446
    [No Abstract]   [Full Text] [Related]  

  • 13. Sirolimus-eluting stents for the treatment of atherosclerotic ostial lesions.
    Aziz S; Ramsdale DR
    J Invasive Cardiol; 2005 Jan; 17(1):13. PubMed ID: 15640532
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized study on provisional stenting with sirolimus-eluting stent vs. bare metal stent for the treatment of true coronary bifurcations: the PROSUMER (PROvisional with sirolimus-eluting vs. bare metal stents in truE bifuRcations) study.
    Tanzilli G; Pelliccia F; Pasceri V; Speciale G; Greco C; Arrivi A; Viceconte N; Mangieri E; Gaudio C
    Int J Cardiol; 2011 Jan; 146(2):240-1. PubMed ID: 21093942
    [No Abstract]   [Full Text] [Related]  

  • 15. Percutaneous stenting of the left main with drug eluting stents for in-stent restenosis: immediate- and long-term results.
    Mixon T; Fitzsimmons P
    J Invasive Cardiol; 2006 Jun; 18(6):E166-8. PubMed ID: 16775892
    [No Abstract]   [Full Text] [Related]  

  • 16. Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease (SCANDSTENT) trial.
    Kelbaek H; Helqvist S; Thuesen L; Kløvgaard L; Jørgensen E; Saunamäki K; Krusell LR; Bøtker HE; Engstrøm T; Jensen GV;
    Am Heart J; 2006 Nov; 152(5):882-6. PubMed ID: 17070149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left main coronary artery stenting: crossing the Rubicon.
    Alfonso F
    J Am Coll Cardiol; 2009 May; 53(19):1769-72. PubMed ID: 19422983
    [No Abstract]   [Full Text] [Related]  

  • 18. Two-year (mid-term) results for unprotected left main coronary artery percutaneous interventions with drug-eluting stents.
    Yarkoni A; Brodsky A; Sabapathy R; Pershad A
    Indian Heart J; 2008; 60(3):195-9. PubMed ID: 19240306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of three or more sirolimus-eluting stents versus paclitaxel-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention.
    Chu WW; Kuchulakanti PK; Torguson R; Wang B; Clavijo LC; Suddath WO; Pichard AD; Satler LF; Kent KM; Waksman R
    Catheter Cardiovasc Interv; 2006 Jul; 68(1):62-6. PubMed ID: 16755592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of complete revascularization with nine sirolimus eluting stents.
    Bardhan AK; Khan A
    Indian Heart J; 2008; 60(2):149-51. PubMed ID: 19218726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.